MIP Discovery announces drugs of abuse reagent launch Novel nanoMIPTM affinity reagents engineered to recognise metabolites of the synthetic opioid, fentanyl are now available for research evaluation. It is hoped that these reagents will help combat the growing wave of deaths in North America attributable to synthetic opioids.
MIP Discovery secures significant funding to support development of global rapid response diagnostics Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries
MIP Discovery Adopts the Fida 1 Platform Funding received from the Bill & Melinda Gates Foundation for rapid deployment of novel detection reagents to support mass scale testing in low to middle-income countries
Rapidly growing nanotechnology firm launches new identity as MIP Discovery MIP Diagnostics, a leading UK nanotechnology firm has today rebranded to MIP Discovery as the business continues its expansion within the healthcare sector.
360Dx feature: COVID-19 MIPs are ‘Showcase’ for company’s future 360Dx, the leading online news platform in the in-vitro diagnostics industry takes a look at MIP Diagnostics technology and future growth.
Stay up to date with the latest news from MIP Discovery
Our website uses cookies to provide you the best experience. However, by continuing to use our website, you agree to our use of cookies. For more information, read our Cookie Policy.
